# A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.

> **NCT01899755** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 45 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** GSK2800528, solution for injection
- **DRUG:** Placebo (0.9% w/v Sodium Chloride), solution for injection
- **DRUG:** Adalimumab, solution for injection

## Key facts

- **NCT ID:** NCT01899755
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-10
- **Primary completion:** 2014-04-03
- **Final completion:** 2014-04-03
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01899755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01899755, "A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01899755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*